PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

NMR in Biomedicine

Volumn 30, Issue 9, 2017, Pages

  Almeida, Gilberto S ^a   Bawn, Carlo M ^a   Galler, Martin ^a   Wilson, Ian ^a   Thomas, Huw D ^a   Kyle, Suzanne ^a   Curtin, Nicola J ^a   Newell, David R ^a   Maxwell, Ross J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

molecular imaging; MRS; NAD+; PARP inhibitor

Indexed keywords

BIOMARKERS; CELL CULTURE; CELLS; CYTOLOGY; DISEASES; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; MAMMALS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHATES; TISSUE;

ADENOSINE DIPHOSPHATE; CANCER CELL LINES; CELLULAR PROCESS; IN-VIVO MEASUREMENT; MULTIFUNCTIONAL PROTEIN; NAD+; PARP-INHIBITOR; PERCHLORIC ACIDS;

TISSUE ENGINEERING;

BIOLOGICAL MARKER; LIVER EXTRACT; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PERCHLORIC ACID; RUCAPARIB; TEMOZOLOMIDE; INDOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

A2780 CELL LINE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KNOCKOUT MOUSE; LIVER TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; WILD TYPE MOUSE; ANIMAL; CHEMISTRY; LIVER; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HUMANS; INDOLES; LIVER; MICE, KNOCKOUT; NAD; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 85019617662     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3736     Document Type: Article

References (39)

1. Orlando L, Schiavone P, Fedele P, et al. Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. Expert Opin Ther Targets. 2012;16(S2):S83-S89.
2. Schreiber V, Dantzer F, Ame J-C, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7(7):517-528.
3. Schreiber V, Hunting D, Trucco C, et al. A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage. Proc Natl Acad Sci U S A. 1995;92(11):4753-4757.
4. Kirkland JB. Poly ADP-ribose polymerase-1 and health. Exp Biol Med. 2010;235(5):561-568.
5. Wang Z-Q, Stingl L, Morrison C, et al. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev. 1997;11(18):2347-2358.
6. Ménissier de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A. 1997;94(14):7303-7307.
7. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med. 2005;7(04):1-20.
8. Ménissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003;22(9):2255-2263.
9. Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3):375-429.
10. Pillai JB, Isbatan A, Imai S-I, Gupta MP. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure Is mediated by NAD+ depletion and reduced Sir2α deacetylase activity. J Biol Chem. 2005;280(52):43121-43130.
11. Abraham P, Rabi S. Nitrosative stress, protein tyrosine nitration, PARP activation and NAD depletion in the kidneys of rats after single dose of cyclophosphamide. Clin Exp Nephrol. 2009;13(4):281-287.
12. Lin T, Yang MS. Benzo[a]pyrene-induced necrosis in the HepG2 cells via PARP-1 activation and NAD+ depletion. Toxicology. 2008;245(1–2):147-153.
13. Bajrami I, Kigozi A, Van Weverwijk A, et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol Med. 2012;4(10):1087-1096.
14. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293-301.
15. Calvert H, Azzariti A. The clinical development of inhibitors of poly(ADP-ribose) polymerase. Ann Oncol. 2011;22(suppl 1):i53-i59.
16. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015;33(12):1397-1406.
17. Plummer R, Middleton M, Wilson R, et al. First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2005;23(16_suppl):3065-3065.
18. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs. 2009;18(1):31-43.
19. 31P MRS measurement of NAD+ and NADH contents in brains. Magn Reson Med. 2014;71(6):1959-1972.
20. Zhu X-H, Lu M, Lee B-Y, Ugurbil K, Chen W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A. 2015;112(9):2876-2881.
21. 1H NMR spectroscopy. NMR Biomed. 2014;27(7):802-809.
22. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102(11):1555-1577.
23. Calabrese CR, Batey MA, Thomas HD, et al. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003;9(7):2711-2718.
24. Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007;6(3):945-956.
25. Ali M, Telfer BA, McCrudden C, et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res. 2009;15(19):6106-6112.
26. Boulton S, Pemberton LC, Porteous JK, et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer. 1995;72(4):849-856.
27. Bhute VJ, Palecek SP. Metabolic responses induced by DNA damage and poly (ADP-ribose) polymerase (PARP) inhibition in MCF-7 cells. Metabolomics. 2015;11(6):1779-1791.
28. Zong W-X, Ditsworth D, Bauer DE, Wang Z-Q, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004;18(11):1272-1282.
29. Murray J, Thomas H, Berry P, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014;110(8):1977-1984.
30. Jackson TM, Rawling JM, Roebuck BD, Kirkland JB. Large supplements of nicotinic acid and nicotinamide increase tissue NAD+ and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats. J Nutr. 1995;125(6):1455-1461.
31. Henning SM, Swendseid ME, Coulson WF. Male rats fed methyl- and folate-deficient diets with or without niacin develop hepatic carcinomas associated with decreased tissue NAD concentrations and altered poly(ADP-ribose) polymerase activity. J Nutr. 1997;127(1):30-36.
32. Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012;30(3):283-288.
33. Antolín AA, Mestres J. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget. 2014;5(10):3023-3028.
34. Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids. 2010;2010, 157591:13.
35. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921.
36. Plummer ER, Middleton MR, Jones C, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-Ribose) polymerase-1. Clin Cancer Res. 2005;11(9):3402-3409.
37. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst. 2002;94(14):1091-1099.
38. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004;96(1):56-67.
39. Braidy N, Lim CK, Grant R, Brew BJ, Guillemin GJ. Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis. Brain Res. 2013;1537:267-272.